李锦;张春燕;彭薇;张民杰;姚宏武;杜明梅;刘运喜;周红辉;

• 1:中国人民解放军总医院医学创新研究部出生缺陷防控技术研究中心
• 2:中国人民解放军总医院第一医学中心疾病预防控制科

摘要(Abstract)：

目的 分析感染新型冠状病毒(SARS-CoV-2)的医护工作人员特异性受体结合结构域(RBD)中和抗体变化，了解高风险人群免疫应答，为后续健康随访提供依据。方法 随机选取2022年12月1日-2022年12月25日某综合医院385例感染SARS-CoV-2在岗医护工作人员，收集流行病学史和临床症状信息，检测末梢血SARS-CoV-2特异性抗体[S-IgM、S-IgG和RBD中和抗体(荧光免疫层析法)]表达水平，JPR模型分析表达趋势。结果 JPR模型分析显示，S-IgM、S-IgG和RBD中和抗体分别在出现症状后4天、6天和6天上升趋势明显，S-IgM在出现症状后8天开始下降。广义线性混合模型多因素分析显示，性别和发热症状均与RBD中和抗体关联性弱；随着年龄增加，RBD中和抗体表达下降；接种疫苗会增加RBD中和抗体表达。结论 SARS-CoV-2特异性抗体S-IgM、S-IgG和RBD中和抗体在出现典型症状后4～6天升高趋势明显，RBD中和抗体维持时间长。此外，随年龄增加，RBD中和抗体水平呈下降趋势。

关键词(KeyWords)： 新型冠状病毒;新型冠状病毒感染;特异性受体结合结构域;抗体;中和活性;流行病学

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划(2020YFC2004604)

作者(Authors): 李锦;张春燕;彭薇;张民杰;姚宏武;杜明梅;刘运喜;周红辉;

参考文献(References)：

• [1] Cameroni E,Bowen JE,Rosen LE,et al.Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift[J].Nature,2022,602(7898):664-670.
• [2] VanBlargan LA,Errico JM,Halfmann PJ,et al.An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies[J].Nat Med,2022,28(3):490-495.
• [3] Bergwerk M,Gonen T,Lustig Y,et al.Covid-19 breakthrough infections in vaccinated health care workers[J].N Engl J Med,2021,385(16):1474-1484.
• [4] Flacco ME,Acuti Martellucci C,Baccolini V,et al.Risk of reinfection and disease after SARS-CoV-2 primary infection:Meta-analysis[J].Eur J Clin Invest,2022,52(10):e13845.
• [5] Malhotra S,Mani K,Lodha R,et al.COVID-19 infection,and reinfection,and vaccine effectiveness against symptomatic infection among health care workers in the setting of omicron variant transmission in New Delhi,India[J].Lancet Reg Health Southeast Asia,2022,3:100023.
• [6] Garcia-Beltran WF,Lam EC,Astudillo MG,et al.COVID-19 neutralizing antibodies predict disease severity and survival[J].medRxiv,2020:2020.10.15.20213512.
• [7] Shang J,Ye G,Shi K,et al.Structural basis of receptor recognition by SARS-CoV-2[J].Nature,2020,581(7807):221-224.
• [8] Walls AC,Park YJ,Tortorici MA,et al.Structure,function,and antigenicity of the SARS-CoV-2 spike glycoprotein[J].Cell,2020,181(2):281-292.e6.
• [9] Tay MZ,Poh CM,Renia L,et al.The trinity of COVID-19:immunity,inflammation and intervention[J].Nat Rev Immunol,2020,20(6):363-374.
• [10] Zheng JX,Deng YY,Zhao ZY,et al.Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects[J].Cell Mol Immunol,2022,19(2):150-157.
• [11] 中华人民共和国国家卫生健康委员会.关于印发新型冠状病毒肺炎防控方案(第九版)的通知[EB/OL].(2022-06-28)[2023-02-11].http://www.nhc.gov.cn/jkj/s3577/202206/de224e7784fe4007b7189c1f1c9d5e85.shtml.
• [12] Lau EHY,Tsang OTY,Hui DSC,et al.Neutralizing antibody titres in SARS-CoV-2 infections[J].Nat Commun,2021,12(1):63.
• [13] Venter M,Richter K.Towards effective diagnostic assays for COVID-19:a review[J].J Clin Pathol,2020,73(7):370-377.
• [14] Nie J,Li Q,Wu J,et al.Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2[J].Emerg Microbes Infect,2020,9(1):680-686.
• [15] Kohmer N,Westhaus S,Ruhl C,et al.Clinical performance of different SARS-CoV-2 IgG antibody tests[J].J Med Virol,2020,92(10):2243-2247.
• [16] Han Y,Liu PP,Qiu Y,et al.Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19[J].JCI Insight,2021,6(4):e146267.
• [17] Carazo S,Skowronski DM,Brisson M,et al.Estimated protection of prior SARS-CoV-2 infection against reinfection with the Omicron variant among messenger RNA-vaccinated and nonvaccinated individuals in Quebec,Canada[J].JAMA Netw Open,2022,5(10):e2236670.
• [18] Gudbjartsson DF,Norddahl GL,Melsted P,et al.Humoral immune response to SARS-CoV-2 in Iceland[J].N Engl J Med,2020,383(18):1724-1734.
• [19] Lou B,Li TD,Zheng SF,et al.Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset[J].Eur Respir J,2020,56(2):2000763.
• [20] Long QX,Liu BZ,Deng HJ,et al.Antibody responses to SARS-CoV-2 in patients with COVID-19[J].Nat Med,2020,26(6):845-848.
• [21] Ripperger TJ,Uhrlaub JL,Watanabe M,et al.Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity[J].Immunity,2020,53(5):925-933.e4.
• [22] Suthar MS,Zimmerman MG,Kauffman RC,et al.Rapid generation of neutralizing antibody responses in COVID-19 patients[J].Cell Rep Med,2020,1(3):100040.
• [23] Huang AT,Garcia-Carreras B,Hitchings MDT,et al.A systematic review of antibody mediated immunity to coronaviruses:antibody kinetics,correlates of protection,and association of antibody responses with severity of disease[J].medRxiv,2020:2020.04.14.20065771.
• [24] Kellam P,Barclay W.The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection[J].J Gen Virol,2020,101(8):791-797.
• [25] Prevost J,Gasser R,Beaudoin-Bussières G,et al.Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike[J].Cell Rep Med,2020,1(7):100126.
• [26] Apostolidis SA,Kakara M,Painter MM,et al.Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy[J].Nat Med,2021,27(11):1990-2001.
• [27] Tober-Lau P,Schwarz T,Vanshylla K,et al.Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers[J].Lancet Respir Med,2021,9(11):e104-e105.